Juvenile Myelomonocytic Leukemia
|
|
0.810 |
CausalMutation
|
CLINVAR |
|
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
UNIPROT |
|
|
|
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
Breast adenocarcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although the G13D KRAS mutation normally predicts an intermediate outcome, the aggressive tumor behavior suggests other modifying factors in rare types of colonic carcinomas.
|
22180717 |
2011 |
Squamous cell carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.
|
30896620 |
2019 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
APLASIA CUTIS CONGENITA WITH EPIBULBAR DERMOIDS
|
|
0.010 |
GeneticVariation
|
BEFREE |
Both diseases were proposed to represent mosaic disorders, but only very recently whole-genome sequencing has led to the identification of somatic KRAS mutations, p.Leu19Phe and p.Gly13Asp, in affected tissue from two individuals with OES.
|
26970110 |
2016 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
|
26623049 |
2015 |
Lymphoma, Follicular
|
|
0.010 |
GeneticVariation
|
BEFREE |
Comparative whole exome sequencing was then performed, which identified a KRAS p.G13D mutation in the LCS that was not present in the FL.
|
30322385 |
2018 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared to patients with c.38G > A (rs112445441, p.G13D), patients with c.*4066delA (rs560890523) and c.38G > A (rs112445441, p.G13D) presented more aggressive tumors with highly invasive features.
|
27256640 |
2017 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
|
21398618 |
2011 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |